Editing RareCan
Revision as of 11:40, 5 July 2022 by Crowdcube (talk | contribs) (Created page with "thumb|RareCan logo == Summary == RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities. * First commercial contract agreed * Over 800 members with rare cancer & 3 charity partnerships in place * NHS Ethics approved process for...")
Warning: You are editing an out-of-date revision of this page. If you publish it, any changes made since this revision will be lost.
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Retrieved from βhttps://stockhub.co/research/RareCanβ